Aldosterone synthase inhibitors

US9073929B2 · kind B2 · utility

Assignees

• ElexoPharm GmbH · DE
• Merck Sharp & Dohme LLC · US

Inventors

• Scott B. Hoyt · Hoboken, US
• Whitney Lane Petrilli · Jersey City, US
• Clare London · Chatham, US
• Yusheng Xiong · Newtown, US
• Jerry Andrew Taylor · Trenton, US
• Amjad Ali · Freehold, US
• Michael Man-Chu Lo · Rahway, US
• Timothy J. Henderson · Natick, US
• Qingzhong Hu · Riegelsberg, DE
• Rolf Hartmann · Saarburg, DE
• Lina Yin · Riegelsberg, DE
• Ralf Heim · Riegelsberg, DE
• Emmanuel Bey · Enzklösterle, DE
• Rohit Saxena · Sidhauli, IN
• Swapan Kumar Samanta · Kanchinakote, IN
• Bheemashankar A. Kulkarni · Noida, IN

Key dates

• Filing date: Apr 20, 2012
• Grant date: Jul 7, 2015
• Expiry date: Apr 20, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention relates to tricyclic triazole analogs of the formula I or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthetase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthetase.